Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News BMS and Otsuka receive FDA approval for Abilifya

BMS and Otsuka receive FDA approval for Abilifya

7th November 2007

Bristol-Myers Squibb (BMS) and Otsuka Pharmaceuticals have announced that the US Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Abilifya in the treatment of schizophrenia in adolescents from 13 to 17 years.

Abilify, the companies’ atypical antipsychotic treatment, is indicated for use in adolescents with positive and negative symptoms of schizophrenia.

The approval comes off the back of a six-week study which demonstrated significant improvements on the primary efficacy endpoint – Positive and Negative Syndrome Scale Total Score, in patients taking Abilify.

Elliot Sigal, executive vice president of BMS, illustrated that schizophrenia was one of the most “complex” of all mental health disorders.

“We remain committed to providing innovative therapies, such as Abilify, to help patients, including adolescents, living with schizophrenia.”

Otsuka’s president Tatsuo Higuchi stated the company’s delight in seeing Abilify’s approval, confirming that the treatment offers an “effective new option” for those suffering with mental illness.

The FDA approved Abilify for the treatment of schizophrenia in adults in November 2002.

Earlier this month, BMS received FDA approval for Ixempra in the treatment of patients with metastatic or locally advanced breast cancer.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.